Just got a sneak peak of the data Alnylam will be presenting next week at the XV International Symposium on Amyloidosis in Uppsala, Sweden.
Kiacta (eprodisate) has had a long history of showing potential for AA amyloidosis then failing to deliver in the end.
The Pan Canadian Pharmaceutical Alliance has called off negotiation with Alexion to allow Soliris to treat Canadians with aHUS.
The Alport Syndrome Foundation (ASF) awarded 3 outstanding Alport syndrome kidney patients the Paul Silver Tribute award.
Attention researchers – you may be eligible to win a $100,000 research grant
The FDA accepted Eisai’s supplemental new drug application for lenvatinib, a potential treatment of patients with advanced or metastatic renal cell carcinoma (RCC) in combination with everolimus, a chemotherapy, following one prior vascular endothelial growth factor (VEGF)-targeted therapy.
Many rare diseases affect the kidneys and the urinary system
Top Orphan Drug Stories for Monday, November 23, 2015
Long-term data for the use Soliris (eculizumab) in patients with atypical hemolytic uremic syndrome (aHUS) show that the orphan approved drug is safe and effective for several years.
Sharon Lagas, president of the Alport Syndrome Foundation talks about the history of the foundation, resources for Alport syndrome patients and upcoming Kidney Week plans